

## 9 Literaturverzeichnis

- 1 Altman DG. Some common problems in medical research. In: Practical statistics for medical research, 8th edn, London, Weinheim, New York: Chapman & Hall, 1998:403-9.
- 2 Ascher B, Klap P, Marion MH, Chanteloub F. Botulinum toxin in the treatment of fronto-glabellar and periorbital wrinkles. An initial study. *Ann Chir Plast Esthet* 1995;40:67-76.
- 3 Bamford J. Interobserver variation in the assessment of rosacea. *Arch Dermatol*. 1998;134:508.
- 4 Baumann L, Slezinger A, Vujevich J et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial. *Dermatol Surg*. 2003;29:508-15.
- 5 Becker-Wegerich P, Neuse W, Ruzicka T. Ästhetische Dermatologie heute: Möglichkeiten und Grenzen. *Gynäkologe* 2003;36:137-48.
- 6 Bentsianov B, Blitzer A. Facial anatomy. *Clin Dermatol*. 2004;22:3-13.
- 7 Bland JM, Altman DG. Validating scales and indexes. *BMJ* 2002;324:606-7.
- 8 Blitzer A, Binder WJ, Brin MF. Management of facial wrinkles with botulinum toxin injections. In: Office-based surgery of the head and neck, Philadelphia: Lippincott-Raven. 1998:251-4.
- 9 Boyer AE, Moura H, Woolfitt AR et al. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. *Anal Chem*. 2005;77:3916-24.
- 10 Breit S, Heckmann M. Botulinum toxin. A neurotoxin for dermatologic therapy. *Hautarzt*. 2000;51:874-91.
- 11 Carruthers J, Carruthers A. The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet Botulinum toxin type A chemodenervation. *Dermatol Surg*. 2004;30:355-66.
- 12 Carruthers J, Fagien S, Matarasso SL: Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. *Plast Reconstr Surg*. 2004;114:1S-22S.
- 13 Carruthers JA, Lowe NJ, Menter MA, et al. BOTOX Glabellar Lines I Study Group. A multi-center, double-blind, randomized, placebo-controlled study of the efficacy and safety of

- botulinum toxin type A in the treatment of glabellar lines. *J Am Acad Dermatol.* 2002;46:840-9.
- 14 Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N. Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. *Plast Reconstr Surg.* 2003;112:1089-98.
  - 15 Cicchetti DV, Allison T. A New Procedure for Assessing Reliability of Scoring EEG Sleep Recordings. *American Journal of EEG Technology* 1971;11:101-9.
  - 16 Cohen J. A coefficient of agreement for nominal scales. *Educational and Psychological Measurement* 1960;20:37-46.
  - 17 Day DJ, Littler CM, Swift RW, Gottlieb S. The wrinkle severity rating scale: a validation study. *Am J Clin Dermatol.* 2004;5:49-52.
  - 18 Ellis DA, Tan AK. Cosmetic upper-facial rejuvenation with botulinum. *J Otolaryngol.* 1997;26:92-6.
  - 19 Erdal E, Bartels F, Binschek T et al. Processing of tetanus and botulinum A neurotoxins in isolated chromaffin cells. *Naunyn Schmiedebergs Arch Pharmacol.* 1995;351:67-78.
  - 20 European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: The SCORAD Index. *Dermatology* 1993;186:23-31.
  - 21 Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. *Plast Reconstr Surg.* 1999;103:701-13.
  - 22 Fagien S. Botulinum toxin type A for facial aesthetic enhancement: role in facial shaping. *Plast Reconstr Surg.* 2003;112:6S-18S.
  - 23 Fleiss JL. Measuring nominal scale agreement among many raters. *Psychological Bulletin* 1971;76:378-81.
  - 24 Frankel AS, Kamer FM. Chemical browlift. *Arch Otolaryngol Head Neck Surg.* 1998;124:321-3.
  - 25 Fredriksson T, Pettersson U. Severe psoriasis – Oral therapy with a new retinoid. *Dermatologica* 1978;157:238-44.
  - 26 Habbema L. Facial esthetics and patient selection. *Clin Dermatol.* 2004;22:14-7.
  - 27 Hatzis J. The wrinkle and its measurement - a skin surface Profilometric method. *Micron.* 2004;35:201-19.
  - 28 Heckmann M, Ceballos-Baumann A, Schaller M, Plewig G. Botulinum-Toxin-A in der Dermatologie. *Hautarzt.* 1998;49:87-90.
  - 29 Heckmann M, Rzany B. Botulinumtoxin in der Dermatologie. Grundlagen und Praktische Anwendung. 1. Aufl. München: Urban und Vogel, 2002.

- 30 Heckmann M, Schon-Hupka G. Quantification of the efficiency of botulinum toxin type A by digital image analysis. *J Am Acad Dermatol*. 2001;45:508-14.
- 31 Honeck P, Weiss C, Sterry W, Rzany B for the GLADYS STUDY GROUP. Reproducibility of a four-point clinical severity score for glabellar frown lines. *Br J Dermatol*. 2003;149:306-10.
- 32 Kane MA. Classification of crow's feet patterns among Caucasian women: the key to individualizing treatment. *Plast Reconstr Surg*. 2003;112:33S-39S.
- 33 Keen M, Blitzer A, Aviv J et al. Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, placebo-controlled study. *Plast Reconstr Surg*. 1994;94:94-9.
- 34 Kim EJ, Ramirez AL, Reeck JB, Maas CS. The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. *Plast Reconstr Surg*. 2003;112:88S-93S.
- 35 Kim EJ, Reeck JB, Maas CS. A validated rating scale for hyperkinetic facial lines. *Arch Facial Plast Surg*. 2004;6:253-6.
- 36 Lemperle G, Holmes RE, Cohen SR, Lemperle SM. A classification of facial wrinkles. *Plast Reconstr Surg*. 2001;108:1735-50.
- 37 Lowe NJ, Asher B, Heckman M et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. *Dermatol Surg*. 2005;31:257-62.
- 38 Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. *J Am Acad Dermatol*. 2002;47:834-40.
- 39 Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: A double-blind, placebo-controlled study with an electromyographic injection technique. *J Am Acad Dermatol*. 1996;35:569-72.
- 40 Matarasso A, Chia C: American Society of Plastic Surgeons DATA Committee. Follow up: Botulinum toxin. *Plast Reconstr Surg*. 2003;112:62S-65S.
- 41 Matarasso A, Deva AK: American Society of Plastic Surgeons DATA Committee. Botulinum toxin. *Plast Reconstr Surg*. 2002;109:1191-7.
- 42 Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. *Dermatol Surg*. 2003;29:7-13.
- 43 Ramirez AL, Reeck J, Maas CS. Preliminary experience with botulinum toxin type B in hyperkinetic facial lines. *Plast Reconstr Surg*. 2002;109:2154-5.
- 44 Ramirez AL, Reeck JB, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. *Otolaryngol Head Neck Surg*. 2002;126:459-67.

- 45 Rauch L, Ruzicka T. Aesthetic dermatology. Botulinumtoxin A and soft tissue augmentation. *Hautarzt*. 2004;55:621-9.
- 46 Rohrich RJ, Janis JE, Fagien S, Stuzin JM. Botulinum toxin: expanding role in medicine. *Plast Reconstr Surg*. 2003;112:1S-3S.
- 47 Rzany B, de Maio M. *Injectible Fillers in Aesthetic Medicine*. 1. Aufl. Berlin: Springer, 2006.
- 48 Rzany B, Philipp A, Schäfer T. Validierung und Reproduzierbarkeit von Kriterien zu Diagnose und Schweregrad der Psoriasis. *Allergo J*. 1997;6:367-68.
- 49 Sadick NS, Matarasso SL. Comparison of botulinum toxins A and B in the treatment of facial rhytides. *Dermatol Clin*. 2004;22:221-6.
- 50 Sadick NS. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. *Dermatol Surg*. 2002;28:817-21.
- 51 Sadick NS. The cosmetic use of botulinum toxin type B in the upper face. *Clin Dermatol*. 2004;22:29-33.
- 52 Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. *Clin Dermatol*. 2004;22:34-9.